title: Benign prostatic hypertrophy: update on drug therapy.
authors.forename: A
authors.initials: A
authors.lastname: Tejani
authors.forename: V
authors.initials: V
authors.lastname: Musini
authors.forename: T L
authors.initials: TL
authors.lastname: Perry
authors.forename: B
authors.initials: B
authors.lastname: Mintzes
authors.forename: J M
authors.initials: JM
authors.lastname: Wright
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D001378:Azasteroids / Q000009:adverse effects / Q000627:therapeutic use; D002170:Canada; D004305:Dose-Response Relationship, Drug; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D018120:Finasteride / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D001378:Azasteroids; D004791:Enzyme Inhibitors; D018120:Finasteride; D000068538:Dutasteride